Belgian AI company Kantify was conducting business as usual until a cancer diagnosis led the team to rethink their direction. “We created algorithms for sectors like marketing or transport,” said Ségolène Martin, Kantify’s co-founder and CEO.
“These were complex projects unrelated to health, but they allowed us to develop deep expertise in AI.”
In 2017, Nik Subramanian, the company’s CTO, was diagnosed with sarcoma, a rare type of cancer that forms tumors in connective tissues such as bones, muscles, and blood vessels.
This experience prompted the company to shift its focus to health and explore the potential of AI to improve how new drugs for rare diseases are identified and tested.
“It changed our lives,” said Martin. “We are now fully focused on AI for human health and have developed a specialized technology for AI-based drug discovery.”
This expertise is now being fully utilized as part of a five-year EU-funded research initiative called DREAMS, which aims to improve treatments for a group of five rare neuromuscular disorders that progressively weaken muscle function.
Increasing the Odds for Patients
“
We are now completely focused on AI for human health, and have developed a specialised technology for AI-based drug discovery.
Developing treatments for rare diseases remains one of the biggest challenges in modern medicine. The process is long, expensive, and uncertain, requiring years of research, regulatory approval, and clinical trials.
For pharmaceutical companies, the small number of patients often makes such investments difficult to justify. As a result, many conditions remain untreated.
Today, only around 5–6% of the estimated 7,000 to 10,000 rare diseases have an approved therapy, a gap highlighted as a global priority by organizations like the World Health Organization.
AI could change that. By rapidly analyzing vast datasets, AI can narrow down potential drug candidates early on and identify existing medicines that might be repurposed for rare conditions.
A Focus on Neuromuscular Disorders
Within DREAMS, researchers focus on five rare neuromuscular disorders, including Duchenne muscular dystrophy, which primarily affects young boys and causes muscle degeneration, and Emery–Dreifuss muscular dystrophy, which can cause severe heart issues.
Although these conditions differ in their genetic causes, they appear to share underlying mechanisms of action at the cellular level. By targeting these common pathways, researchers hope to develop treatments beneficial to several diseases at once, rather than tackling each one separately.
The team reprograms patient cells into induced pluripotent stem cells (iPSCs) – a type of master cell that can be turned into many other cell types – and then turns them into skeletal muscle tissue, allowing researchers to study the disease in a controlled setting.
By combining these lab models with AI, researchers can identify shared therapeutic targets across multiple conditions.
“This kind of research is crucial for patients and their families,” said Xavier Nissan, project coordinator of DREAMS and research director at French research institute I-Stem specializing in stem cell therapy and the treatment of monogenic diseases.
“They are suffering and have to deal with their disease every day. They need technology like this.”
From Data to Potential Treatments
As well as identifying underlying disease processes, the DREAMS researchers use AI to analyze billions of new and existing drugs to predict which compounds are most likely to work.
“This is one of the ways in which AI can generate real societal value,” said Martin. “It can truly accelerate research and create impact in areas where progress has been slow.”
In the lab, the team tests a library of 2,700 EMA- and FDA-approved drugs to assess whether any could improve shared disease-related symptoms.
“In the lab, we test thousands of existing drugs on iPSC-derived muscle cells from patients with these
Comments
20 responses to “AI Joins the Search for New Rare Disease Treatments”
-
Looks like Kantify’s got a new trick up its sleeve—turning a cancer scare into a high-tech health revolution! Who knew algorithms could be more than just fancy number crunchers? 🤖💉 #InnovationOrDesperation
-
You’d think AI was the magic cure-all for everything, right? 🤖 But here we are, turning rare diseases into a fancy game of “find the needle in the haystack” – and let’s hope they don’t lose the needle while it’s at it! 🏥💊
-
Just what we needed—another fancy algorithm to save the day! Because, you know, we’ve totally mastered the art of curing all the common ailments, so let’s tackle the rare stuff with a sprinkle of AI magic! 🧙♂️💊
-
Oh, fantastic! Finally, AI is tackling rare diseases—just what we needed, a robot playing doctor. Next thing you know, they’ll be hosting the next health summit in a silicon chip! 😂
-
Blimey, AI’s now playing doctor, eh? Next thing you know, it’ll be prescribing pints instead of pills! 🍻😜
-
Oh joy, another AI miracle in healthcare! Just what we needed—because who wouldn’t want their rare disease treatment to be found by a computer that thinks it’s smarter than the average doctor? 🤖💊
-
Just what we needed—AI swooping in to save the day in the drug biz. I suppose the robots will be writing prescriptions next! 😂💊
-
So, let me get this straight: a bunch of tech whizzes decide to swap their marketing algorithms for life-saving AI? Who knew playing with data could actually do something useful! 🤷♂️
-
Right, so we’ve got AI hunting for rare disease treatments now—because clearly, algorithms are the new doctors. I suppose next we’ll be asking our fridge for health advice! 🤖🍕
-
So, let me get this straight: we’ve got a bunch of tech whizzes using AI to tackle rare diseases while the rest of us are still trying to figure out how to order a decent coffee in Brussels? 😂 Sounds like a right laugh!
-
Oh, brilliant! Just what we need—AI to save us from rare diseases while we’re still figuring out how to use it to find our car keys. If only it could tackle my paperwork as swiftly! 😏
-
A rare disease treatment powered by AI? Brilliant! Because we all know how quickly the EU can solve problems – just look at the last time they tackled a simple cheese regulation 😏🧀.
-
Absolutely brilliant, isn’t it? Who knew that after all those years of creating algorithms for marketing and transport, a cancer scare would finally point them in the right direction—towards saving lives instead of just boosting sales? 🥳
-
Brilliant! Who knew AI could play doctor? 🚀 I suppose next, it’ll be diagnosing our hangovers from last night’s ‘business meeting’ too! 🍻
-
Looks like AI’s finally decided to swap marketing for medicine—talk about a career change! Who knew crunching numbers could lead to saving lives? 😂
-
Oh, fantastic! Just what we needed—AI playing doctor while we’re still trying to figure out our own GPS! I can already see it now: “Congratulations, your new treatment is… a digital headache!” 😂
-
Can’t wait to see AI save the day in healthcare while we’re still trying to figure out how to parallel park without hitting the curb. 🚗💥 Who knew algorithms had such a flair for treating diseases?
-
Blimey, who knew AI could cure rare diseases while also juggling marketing strategies? Must be nice to have that kind of talent—if only it worked on my tax returns too! 😂💼
-
Ain’t it charming when AI, usually busy figuring out how to sell more shoes, suddenly decides it’s a medical genius? 🤖💊 Just what we needed, algorithms in a lab coat!
-
So, let me get this straight: AI, that magical gizmo we all love to hate, is now the knight in shining armor for rare diseases? Brilliant! Just what we needed — more tech in healthcare! 😂
Last News
Germany and Curaçao Open a World Cup Story About Scale
The four-time champions start off in Houston against the smallest nation ever to qualify for the tournament
Germany’s World Cup kickoff against Curaçao in Houston goes beyond a clash between a European powerhouse and a newcomer. It serves as an early gauge of the expanded tournament’s potential: pressure for established teams, exposure for smaller football nations, and a reminder of
Bardella warns Brussels he won’t moderate
CPMR Applauds EU’s Ambitious New Islands Strategy
The initiative, unveiled on Wednesday, marks the first attempt to give Europe’s islands and coastal areas a more coherent policy framework.
The European Commission formally adopted two dedicated strategies, one for EU islands and one for EU coastal communities.
This sets out for the first time a coordinate
Europe Cannot Ignore the Argument of a Post-Gaza World
Donald Trump’s Least Favorite Country Might Win His World Cup
His administration strongly supports immigration on economic and humanitarian grounds and is in the process of legalizing the status o
Belgium Military Wives Choir: A "Lifeline" for Women
One of the less well publicised aspects of a career in the armed forces is the constant moving around it may involve.
That is where a military choir really can come into its own…a lifeline for women who have had to move around a lot from base to base with their partners.
It is, of course, a wonderful outlet for those with a bent for singi
Swiss Voters Poised to Reject Population Limit
Initial projections indicate a defeat for a right-wing proposal that risked free movement ties with the European Union
Swiss voters appeared set on Sunday to dismiss a proposal to limit the country’s population to 10 million, reducing immediate pressure on Switzerland’s relationship with the European Union while leaving domestic concerns over housing, infrastructure, and migration that fue
Switzerland Rejects Population Limit in Referendum
The referendum was initiated by
Growing Fears of Iranian Cyberattacks Prompt Governments to Bolster Digital Defenses
TEHRAN, Iran, June 14 – Eurotoday — Iran cyberattack concerns are gaining renewed attention as governments, cybersecurity experts, and critical infrastructure operators increase monitoring of digital threats amid heightened geopolitical tensions across the Middle East.
Cybersecurity has become a major component of national security planning, with officials around the world recognizing that moder
Deutsche Börse Carve-Out Reveals EU Market Fault Line
A reported exemption for Deutsche Börse from mandatory EU-level supervision has highlighted an institutional challenge in Brussels’ capital markets reform. This dispute extends beyond one exchange group, questioning if the EU can establish a deeper financial single market while member states maintain
Leave a Reply